180 Life Sciences Corp (ATNF)

$1.56 -0.02 (-1.27%)
Market Cap 1.62M
Revenue (ttm) 0.00
Net Income (ttm) -19.94M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 90,100
Avg Vol 522,346
Day's Range N/A - N/A
Shares Out 1.03M
Stochastic %K 48%
Beta 0.13
Analysts Strong Buy
Price Target $4.00

Latest News on ATNF

180 Life Sciences Corp. Announces Pricing of $2.9 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under NASDAQ Rules

Dec 27, 2024, 9:00 AM EST - 22 days ago

180 Life Sciences Corp. Announces Pricing of $2.9 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under NASDAQ Rules

180 Life Sciences Corp. Regains Full Compliance with Nasdaq Continued Listing Rules

Dec 12, 2024, 8:00 AM EST - 5 weeks ago

180 Life Sciences Corp. Regains Full Compliance with Nasdaq Continued Listing Rules

180 Life Sciences Corp. Announces the Appointment of Stephen Shoemaker to Board of Directors

Dec 4, 2024, 8:00 AM EST - 6 weeks ago

180 Life Sciences Corp. Announces the Appointment of Stephen Shoemaker to Board of Directors

180 Life Sciences Corp. Retains Senior Technology Consultant and Commences Gaming Technology Platform Integration

Oct 31, 2024, 8:00 AM EDT - 2 months ago

180 Life Sciences Corp. Retains Senior Technology Consultant and Commences Gaming Technology Platform Integration

180 Life Sciences Corp. Appoints Mr. Jay Goodman to Board of Directors

Oct 29, 2024, 8:00 AM EDT - 2 months ago

180 Life Sciences Corp. Appoints Mr. Jay Goodman to Board of Directors

This biotech stock soared a whopping 900% on Wednesday: here's why

Oct 16, 2024, 4:03 PM EDT - 3 months ago

This biotech stock soared a whopping 900% on Wednesday: here's why

180 Life Sciences Corp. Interim CEO, Blair Jordan, Issues Letter to Stockholders; Provides Update on Newly Acquired Gaming Technology Platform

Oct 16, 2024, 8:00 AM EDT - 3 months ago

180 Life Sciences Corp. Interim CEO, Blair Jordan, Issues Letter to Stockholders; Provides Update on Newly Acquired Gaming Technology Platform

180 Life Sciences Corp. Regains Compliance with Nasdaq's Minimum Stockholders' Equity Rule and Expands into the Global iGaming Sector

Oct 9, 2024, 8:30 AM EDT - 3 months ago

180 Life Sciences Corp. Regains Compliance with Nasdaq's Minimum Stockholders' Equity Rule and Expands into the Global iGaming Sector

180 Life Sciences Corp. - Corporate Updates

Oct 3, 2024, 8:30 AM EDT - 3 months ago

180 Life Sciences Corp. - Corporate Updates

180 Life Sciences Announces the Appointment of Omar Jimenez as Chief Financial Officer

Sep 12, 2024, 4:15 PM EDT - 4 months ago

180 Life Sciences Announces the Appointment of Omar Jimenez as Chief Financial Officer

180 Life Sciences Announces Positive Topline Results of a Clinical Pharmacology Study Testing a New Solid Formulation of CBD with Enhanced Oral Uptake

Jul 30, 2024, 8:00 AM EDT - 6 months ago

180 Life Sciences Announces Positive Topline Results of a Clinical Pharmacology Study Testing a New Solid Formulation of CBD with Enhanced Oral Uptake

180 Life Sciences Granted Extension by Nasdaq Hearing Panel to Regain Compliance with Continued Listing Requirements

Jul 2, 2024, 8:30 AM EDT - 7 months ago

180 Life Sciences Granted Extension by Nasdaq Hearing Panel to Regain Compliance with Continued Listing Requirements

180 Life Sciences Regains Full Compliance with Nasdaq Minimum Bid Price Requirement

Mar 14, 2024, 8:30 AM EDT - 11 months ago

180 Life Sciences Regains Full Compliance with Nasdaq Minimum Bid Price Requirement

180 Life Sciences Corp. Announces 1-For 19 Reverse Stock Split as Part of Nasdaq Compliance Plan

Feb 26, 2024, 7:00 AM EST - 11 months ago

180 Life Sciences Corp. Announces 1-For 19 Reverse Stock Split as Part of Nasdaq Compliance Plan

180 Life Sciences Engages Financial Advisor to Explore Strategic Alternatives

Dec 4, 2023, 9:00 AM EST - 1 year ago

180 Life Sciences Engages Financial Advisor to Explore Strategic Alternatives

180 Life Sciences Announces Review of Strategic Alternatives

Nov 28, 2023, 9:00 AM EST - 1 year ago

180 Life Sciences Announces Review of Strategic Alternatives

180 Life Sciences Corp. Announces Closing of $3 Million Public Offering

Aug 14, 2023, 4:29 PM EDT - 1 year ago

180 Life Sciences Corp. Announces Closing of $3 Million Public Offering

180 Life Sciences Corp. Announces Pricing of $3 Million Public Offering

Aug 10, 2023, 8:46 AM EDT - 1 year ago

180 Life Sciences Corp. Announces Pricing of $3 Million Public Offering

180 Life Sciences Announces an Agreement for a Clinical Pharmacology Study Testing a New Formulation of CBD for Enhanced Oral Uptake

Aug 7, 2023, 9:00 AM EDT - 1 year ago

180 Life Sciences Announces an Agreement for a Clinical Pharmacology Study Testing a New Formulation of CBD for Enhanced Oral Uptake

180 Life Sciences Corp. Announces Closing of $3 Million Registered Direct Offering and Concurrent Private Placement

Apr 10, 2023, 4:30 PM EDT - 1 year ago

180 Life Sciences Corp. Announces Closing of $3 Million Registered Direct Offering and Concurrent Private Placement

180 Life Sciences Corp. Announces $3 Million Registered Direct Offering and Concurrent Private Placement

Apr 5, 2023, 1:00 PM EDT - 1 year ago

180 Life Sciences Corp. Announces $3 Million Registered Direct Offering and Concurrent Private Placement

180 Life Sciences Announces Presentation at the Gordon Conference

Feb 27, 2023, 8:30 AM EST - 2 years ago

180 Life Sciences Announces Presentation at the Gordon Conference

180 Life Sciences Announces Allowance of Claims for a US Patent for Dupuytren's Disease Treatment and Application

Feb 23, 2023, 7:30 AM EST - 2 years ago

180 Life Sciences Announces Allowance of Claims for a US Patent for Dupuytren's Disease Treatment and Application

180 Life Sciences Provides Update Regarding Anti-TNF Frozen Shoulder Trial

Feb 22, 2023, 4:30 PM EST - 2 years ago

180 Life Sciences Provides Update Regarding Anti-TNF Frozen Shoulder Trial

180 Life Sciences Announces Publication of a Review on the Treatments for Early Stage Dupuytren's Disease

Jan 25, 2023, 8:45 AM EST - 2 years ago

180 Life Sciences Announces Publication of a Review on the Treatments for Early Stage Dupuytren's Disease

Newman Ferrara LLP Investigating Officers and Directors of 180 Life Sciences Corp. (ATNF)

Jan 10, 2023, 1:56 PM EST - 2 years ago

Newman Ferrara LLP Investigating Officers and Directors of 180 Life Sciences Corp. (ATNF)

180 Life Sciences Announces Publication of a Review on the Biological Basis of Dupuytren's Disease

Jan 4, 2023, 8:30 AM EST - 2 years ago

180 Life Sciences Announces Publication of a Review on the Biological Basis of Dupuytren's Disease

180 Life Sciences Corp. CEO James Woody, MD, PhD Issues Letter to Shareholders

Dec 29, 2022, 8:30 AM EST - 2 years ago

180 Life Sciences Corp. CEO James Woody, MD, PhD Issues Letter to Shareholders

180 Life Sciences Corp. Announces Closing of $6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Dec 23, 2022, 8:00 AM EST - 2 years ago

180 Life Sciences Corp. Announces Closing of $6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

180 Life Sciences Corp. Announces $6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Dec 20, 2022, 2:11 PM EST - 2 years ago

180 Life Sciences Corp. Announces $6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

180 Life Sciences Corp. Announces 1-for 20 Reverse Stock Split as Part of Nasdaq Compliance Plan

Dec 16, 2022, 9:00 AM EST - 2 years ago

180 Life Sciences Corp. Announces 1-for 20 Reverse Stock Split as Part of Nasdaq Compliance Plan

180 Life Sciences Provides Update on Progress To Seek Medicines and Healthcare Products Regulatory Agency Marketing Authorization for Anti-TNF Treatment of Early Stage Dupuytren's Contracture

Nov 30, 2022, 5:00 PM EST - 2 years ago

180 Life Sciences Provides Update on Progress To Seek Medicines and Healthcare Products Regulatory Agency Marketing Authorization for Anti-TNF Treatment of Early Stage Dupuytren's Contracture

180 Life Sciences to Participate in A.G.P.'s Virtual Biotech Conference to be Held November 30 – December 1, 2022

Nov 21, 2022, 8:30 AM EST - 2 years ago

180 Life Sciences to Participate in A.G.P.'s Virtual Biotech Conference to be Held November 30 – December 1, 2022

CORRECTION: Adalimumab Found To Be A Likely Cost-Effective Treatment for Early-Stage Dupuytren's Disease

Nov 15, 2022, 12:37 PM EST - 2 years ago

CORRECTION: Adalimumab Found To Be A Likely Cost-Effective Treatment for Early-Stage Dupuytren's Disease

180 Life Sciences Issues Letter to Stockholders

Sep 26, 2022, 8:30 AM EDT - 2 years ago

180 Life Sciences Issues Letter to Stockholders

180 Life Sciences with the University of Oxford Announce the Enrollment of the First Patient in a Trial of Anti-TNF for People with Early-Stage Frozen Shoulder

Aug 22, 2022, 8:30 AM EDT - 2 years ago

180 Life Sciences with the University of Oxford Announce the Enrollment of the First Patient in a Trial of Anti-TNF for People with Early-Stage Frozen Shoulder

180 Life Sciences Announces That the University of Oxford Has Been Awarded a Grant From the National Institute for Health and Care Research in the U.K. to Conduct a Clinical Trial in Post Operative Delirium/Cognitive Deficit in a Jointly Funded Program Wi

Jul 27, 2022, 8:30 AM EDT - 2 years ago

180 Life Sciences Announces That the University of Oxford Has Been Awarded a Grant From the National Institute for Health and Care Research in the U.K. to Conduct a Clinical Trial in Post Operative Delirium/Cognitive Deficit in a Jointly Funded Program Wi

180 Life Sciences Corp. Announces $6.5 Million Registered Direct Offering

Jul 18, 2022, 8:30 AM EDT - 2 years ago

180 Life Sciences Corp. Announces $6.5 Million Registered Direct Offering

180 Life Sciences Corp. Issues Letter to Stockholders

Jun 22, 2022, 4:05 PM EDT - 2 years ago

180 Life Sciences Corp. Issues Letter to Stockholders

Why 180 Life Sciences Shares Are Plunging Today

Jun 15, 2022, 8:28 AM EDT - 2 years ago

Why 180 Life Sciences Shares Are Plunging Today

180 Life Sciences Provides Update on Correspondence Received from U.K. and U.S. Regulatory Authorities on Pathway for a Therapy That Could Prevent Progression of Early-Stage Dupuytren's Disease

Jun 14, 2022, 4:15 PM EDT - 2 years ago

180 Life Sciences Provides Update on Correspondence Received from U.K. and U.S. Regulatory Authorities on Pathway for a Therapy That Could Prevent Progression of Early-Stage Dupuytren's Disease

180 Life Sciences Begins Consultations with UK and US Regulatory Authorities on Pathway for a Therapy that Could Prevent Progression of Early-Stage Dupuytren's Disease

May 31, 2022, 8:30 AM EDT - 2 years ago

180 Life Sciences Begins Consultations with UK and US Regulatory Authorities on Pathway for a Therapy that Could Prevent Progression of Early-Stage Dupuytren's Disease

180 Life Sciences and University of Oxford Announce Publication of Positive Phase 2b Dupuytren's Disease Study Results in The Lancet Rheumatology

Apr 29, 2022, 6:32 PM EDT - 2 years ago

180 Life Sciences and University of Oxford Announce Publication of Positive Phase 2b Dupuytren's Disease Study Results in The Lancet Rheumatology

180 Life Sciences Corp. Forms Scientific Advisory Board

Feb 17, 2022, 8:30 AM EST - 3 years ago

180 Life Sciences Corp. Forms Scientific Advisory Board

180 Life Sciences Corp. To Participate in the Biotech Showcase 2022 Virtual Conference To be Held January 10-12, 2022

Dec 28, 2021, 11:00 AM EST - 3 years ago

180 Life Sciences Corp. To Participate in the Biotech Showcase 2022 Virtual Conference To be Held January 10-12, 2022

180 Life Sciences Corp. Enters into a License Agreement with University of Oxford for Regenerative Molecule HMGB1 for Liver Diseases

Dec 15, 2021, 8:15 AM EST - 3 years ago

180 Life Sciences Corp. Enters into a License Agreement with University of Oxford for Regenerative Molecule HMGB1 for Liver Diseases

180 Life Sciences Provides Follow-Up Information on Oxford University and the Company's Successful Dupuytren's Phase 2b Clinical Trial Results

Dec 6, 2021, 8:15 AM EST - 3 years ago

180 Life Sciences Provides Follow-Up Information on Oxford University and the Company's Successful Dupuytren's Phase 2b Clinical Trial Results

180 Life Sciences Corp. Co-Founder Prof. Jagdeep Nanchahal Presents Keynote Address at the 2021 International Dupuytren Symposium, Including Top Line Data From the Phase 2b Clinical Trial

Dec 1, 2021, 2:45 PM EST - 3 years ago

180 Life Sciences Corp. Co-Founder Prof. Jagdeep Nanchahal Presents Keynote Address at the 2021 International Dupuytren Symposium, Including Top Line Data From the Phase 2b Clinical Trial

180 Life Sciences Corp. Expands Patent Portfolio

Nov 22, 2021, 8:30 AM EST - 3 years ago

180 Life Sciences Corp. Expands Patent Portfolio

180 Life Sciences Corp. Co-Founder Prof. Jagdeep Nanchahal to Present a Keynote Address at the 2021 International Dupuytren Symposium

Nov 18, 2021, 8:15 AM EST - 3 years ago

180 Life Sciences Corp. Co-Founder Prof. Jagdeep Nanchahal to Present a Keynote Address at the 2021 International Dupuytren Symposium